Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma

Glioblastoma (GB) is the most common malignant brain tumor. Drug resistance frequently develops in these tumors during chemotherapy. Therefore, predicting drug response in these patients remains a major challenge in the clinic. Thus, to improve the clinical outcome, more effective and tolerable comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Arabinda, Cheng, Ron Ron, Hilbert, Megan L.T., Dixon-Moh, Yaenette N., Decandio, Michele, Vandergrift, William Alex, Banik, Naren L., Lindhorst, Scott M., Cachia, David, Varma, Abhay K., Patel, Sunil J., Giglio, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667559/
https://www.ncbi.nlm.nih.gov/pubmed/26648752
http://dx.doi.org/10.4137/CGM.S32801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667559/
https://www.ncbi.nlm.nih.gov/pubmed/26648752
http://dx.doi.org/10.4137/CGM.S32801

Ejemplares similares